Aerovance

edit

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovant™, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aeroderm™, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

Milestones

edit

• Received $38M in Unattributed funding. (4/7/09)
  Posted 4/10/09 at 8:36am
• Received $20M in Debt funding. (3/28/08)
  Posted 6/18/09 at 3:20pm
• Received $60M in Series C funding. (3/28/07)
  Posted 6/19/09 at 10:47am

Videos

Screenshots

edit

Sources

1. Aerovance, asthma treatment company, finishes raising $60M (deals.venturebeat.com) [edit]
2. Aerovance Secures $20 Million in Debt Financing (prnewswire.com) [edit]
3. Aerovance inhales $38M for asthma drugs (venturebeat.com) [edit]